FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma By Ogkologos - November 6, 2025 108 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DREAMM-7 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Cancer vaccines – where are we? February 24, 2023 Thinking outside the box to tackle an aggressive children’s cancer September 8, 2021 Study Shows 4 Drugs Better Than 3 for Women with HER2-Positive... June 21, 2021 Experts Think Medical Detection Dogs Could Be Trained To Sniff Out... March 27, 2020 Load more HOT NEWS Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed... How to Spot Suspicious Herb and Supplement Claims During Cancer Inpatient Mammography May Help Solve Issue of Low Screening Rates, Especially... Breast Cancer Survivors in Happy Romantic Relationships Are Healthier, Study Says
